NCT01820858View on ClinicalTrials.gov

The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Endometrial Neoplasms
Interventions
DRUG

Paclitaxel

175 mg/m(2), intravenously (IV)

DRUG

Paraplatin (Carboplatin Injection)

AUC=5, IV

RADIATION

Pelvic Radiation

45-50 Gy

RADIATION

Vaginal Brachytherapy 1

5 Gy, 3 times

RADIATION

Vaginal brachytherapy 2

5 Gy, 2-4 times

Trial Locations (3)

250012

Qilu Hospital，Shandong University, Jinan

310006

Women's Hospital, School of Medicine, Zhejiang University, Hangzhou

430030

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Shandong University

OTHER

collaborator

Huazhong University of Science and Technology

OTHER

collaborator

Zhejiang University

OTHER

lead

Ding Ma

OTHER

NCT01820858 - The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma | Biotech Hunter | Biotech Hunter